Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

VYD222

Other · developed by Invivyd

Phase 3 Most advanced trial (none active)

IVVD Developer

2 Registered trials

What is VYD222?

VYD222 is an investigational drug studied in COVID-19, SARS-CoV-2.

At a glance

Drug type: Other
Therapy area: Infectious disease
Developer: Invivyd, Inc. (IVVD)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06039449	Phase 3	COVID-19	Completed	IVVD
NCT05791318	Phase 1	COVID-19	Completed	IVVD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

COVID-19SARS-CoV-2

More from Invivyd

Adintrevimab Phase 2/3 VYD2311 Phase 3

Sources

ClinicalTrials.gov NCT06039449

Updated Oct 3, 2026. Something wrong or missing? Report it on the IVVD page.

Follow IVVD, the company behind VYD222

See IVVD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

IVVD catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z